Development and Validation of a Novel Functional Eye-Tracking Software Application for Alzheimer's Disease

Inclusion Criteria:

• For all participants:

1. Able to provide informed consent
2. Aged 18 years or older at the time of enrollment
3. Able to read in either French or English
4. Visual acuity of 20/100 in at least one eye (corrective glasses, contact lenses,surgery etc. are permitted)

• For patients only:

1. Confirmed diagnosis of AD based on the NIAAA diagnostic criteria of probable AD
2. Having undergone a full neuropsychological evaluation within the last 6 months orhaving a planned full neuropsychological evaluation within the next 6 months.
3. AD diagnoses supported by FDG-PET scan or amyloid biomarkers (CSF or amyloid PET)

Exclusion Criteria:

• For AD participants:

1. Diagnosed with one of the following dementia subtypes: Fronto-temporal dementia,Lewy-body dementia, or Creutzfeldt-Jakob disease.
2. Incapacity to provide informed consent or inability to adequately understand thetask instructions.

• For all participants:

1. Evidence or medical history of psychiatric issues, which are known to also affectmovements and oculomotor control.
2. Presence of comorbid neurological conditions to avoid eye movement anomalyconfounds (strabismus, cranial nerve palsy, stroke-causing hemianopsia).
3. Diagnosis of macular edema or other pre-existing ocular conditions (e.g.,glaucoma, cataracts) that would prevent from performing the eye movementassessments.
4. Unstable medication use: recent (less than one month from enrollment) start of,change of dose, or irregular use of, new prescription drugs known to have aneffect on ocular motor visual function, such as benzodiazepines, antipsychoticsand anticonvulsants. Occasional use of benzodiazepines for medical procedures ispermitted, at the investigator's discretion, but should not occur within a shorttime period of an eye movement assessment.
5. Diagnosed with an active substance use disorder.
6. History of stroke.
7. Recent traumatic brain injury (within the last 6 months).

• For healthy controls only:

1. Evidence or history of significant neurodegenerative disorder affecting brainfunction (e.g., MS, PD, ALS, Non-AD Dementia)